This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer. Chemotherapy drugs, such as fludarabine, thiotepa, etoposide, melphalan, and rabbit anti-thymocyte globulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.
PRIMARY OBJECTIVE: I. To assess tolerability of allogenic hematopoietic cell transplantation (HCT) among patients with chemo-responsive high-grade central nervous system (CNS) malignancies as defined by transplant-related mortality (TRM) at day 30 as well as rate of grade III organ toxicity or higher (Bearman Regimen-Related Toxicities Scale) attributable to conditioning occurring within 30 days. SECONDARY OBJECTIVES: I. Median time to platelet and neutrophil engraftment. II. Incidence of acute graft-versus-host disease (aGVHD) by day 100. III. Incidence of chronic GVHD at day 100 and one year. IV. Rate of grade II organ toxicity through day 100. V. Rate of graft failure (primary and secondary) through day 100. VI. Rate of infectious complications through day 100. VII. Progression free survival at day 180. VIII. Cumulative incidence of relapse, overall survival, and progression-free survival at 100 days and 1 year. OUTLINE: Patients receive thiotepa intravenously (IV) over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning on day -2 to and mycophenolate mofetil orally (PO) every 8 hours or IV from days 0-40 and tapered to day 90. After completion of study treatment, patients are followed up at 100, 180, 270 and 360 days.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Given IV
Given IV
Undergo HCT
Given IV
Given IV
Given PO or IV
Given IV
Given IV
Transplant-related mortality
Will be reported together with the corresponding 95% Bayesian credible interval. Will be estimated using the method of Gooley.
Time frame: At day 30
Rate of grade III or higher organ toxicity attributable to conditioning
Assessed per Bearman Regimen-Related Toxicities Scale. Will be reported together with the corresponding 95% Bayesian credible interval.
Time frame: Within 30 days
Failure of platelet and neutrophil engraftment rates
Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.
Time frame: Day 100
Incidence of acute graft-versus-host (GVHD) disease
Will be estimated using the method of Gooley.
Time frame: Up to day 100
Incidence of chronic GVHD
Will be estimated using the method of Gooley.
Time frame: At day 100 and 1 year
Rate of grade II organ toxicity
Will be reported as counts with percentages.
Time frame: Up to day 100
Rate of graft failure (primary and secondary)
Will be reported as counts with percentages.
Time frame: Up to day 100
Rate of infectious complications
Will be reported as counts with percentages.
Time frame: Up to day 100
Progression free survival
Time frame: At day 180
Cumulative incidence of relapse
Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.
Time frame: At day 100 and 1 year
Overall survival
Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.
Time frame: At day 100 and 1 year
Progression-free survival
Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.
Time frame: At day 100 and 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.